MedTrace Logo

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia

NCT00004084 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2011-06-22

No results posted yet for this study

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have lymphoma or leukemia that has not responded to previous chemotherapy.

Conditions

Interventions

RADIATION

indium In 111 LL2 IgG

single dose, intravenous infusion over 30 minutes

RADIATION

yttrium Y 90 epratuzumab

single dose, intravenous infusion over 30 minutes

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Garden State Cancer Center at the Center for Molecular Medicine and Immunology

    lead OTHER

Principal Investigators

  • Jack D. Burton, MD · Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2002-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004084 on ClinicalTrials.gov